
7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit

Catalog # KA1293 Size 1 Kit

Applications



Flow Cytometry

The degree of cytotoxicity of natural killer cells (effector cells; NK cells) on K-562 cells (target cells) depends on the ratio of NK cells to K-562 cells. K-562 cells were labeled with CFSE and co-cultured with NK cells at the ratios indicated above. Cells were co-cultured for four hours at 37°C. At the end of the experiment, dead cells were labeled with 7-AAD. The percentage of K-562 cell death was analyzed by a flow cytometer. When K-562 cells were cultured alone, there is little cell death (2%). Addition of NK cells at a ratio as low as 6.25 : 1 caused a significant increase in K-562 cell death (8.2%). At a ratio of NK cells to target cells of 25 : 1, there is 19.7% death of K-562 cells.

Specification

Product Description	7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit is a fluorescence-labeled method for determining the cytotoxic effect of immune effector cells at a single cell level.
Regulation Status	For research use only (RUO)
Storage Instruction	Store the kit at -20°C temporarily. For best results, store the components as described in the protocol.

Applications

Copyright © 2023 Abnova Corporation. All Rights Reserved.

- Flow Cytometry

The degree of cytotoxicity of natural killer cells (effector cells; NK cells) on K-562 cells (target cells) depends on the ratio of NK cells to K-562 cells. K-562 cells were labeled with CFSE and co-cultured with NK cells at the ratios indicated above. Cells were co-cultured for four hours at 37°C. At the end of the experiment, dead cells were labeled with 7-AAD. The percentage of K-562 cell death was analyzed by a flow cytometer. When K-562 cells were cultured alone, there is little cell death (2%). Addition of NK cells at a ratio as low as 6.25 : 1 caused a significant increase in K-562 cell death (8.2%). At a ratio of NK cells to target cells of 25 : 1, there is 19.7% death of K-562 cells.

Publication Reference

- A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer.

Jing Lin, Wenchao Xu, Leiming Xia, Congshu Zhang, Lei Ge, Junfeng Gao, Jian Bao, Yang Xu, Xiang Sun, Hongxia Li, Yi Wang

BMC Pulm Med 2025 Oct; 25(1):482.

- Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.

Wuguang Lu, Lingchong Qiu, Zhanpeng Yan, Zhibing Lin, Meng Cao, Chunping Hu, Zhigang Wang, Jin Wang, Ye Yu, Xiaoyang Cheng, Peng Cao, Rongxiu Li

Oncotarget 2015 Oct; 6(33):34537-48.

Copyright © 2023 Abnova Corporation. All Rights Reserved.